GNS.L vs ZTS
GNS.L: A global leader in animal genetics, using biotechnology to improve the quality and efficiency of livestock production. ZTS: Zoetis is the world's leading animal health company, providing a comprehensive portfolio of medicines, vaccines, and diagnostic technologies for both pets and livestock.
Side-by-side fundamentals
| Metric | GNS.L | ZTS | Edge |
|---|---|---|---|
| Price as of 2026-08-03 close | £22.10 | $74.39 | |
| Market cap as of 2026-08-06 | n/a | $31.2B | |
| P/E as of 2026-08-06 | n/a | 12.06 | |
| PEG as of 2026-08-06 | n/a | 1.59 | |
| Net margin as of 2026-08-06 | n/a | +27.8% | |
| Gross margin as of 2026-08-06 | n/a | +71.8% | |
| Operating margin as of 2026-08-06 | n/a | +34.8% | |
| ROE as of 2026-08-06 | n/a | +62.4% | |
| ROA as of 2026-08-06 | n/a | +17.5% | |
| Debt / equity as of 2026-08-06 | n/a | 2.80 | |
| Revenue growth (YoY) as of 2026-08-06 | n/a | +2.4% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +5.4% | |
| Dividend yield as of 2026-08-06 | n/a | +1.6% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-06 | n/a | 0.73 | |
| 1-year return as of 2026-08-03 close | -11.2% | -49.1% | GNS.L higher |
Fundamentals: market data, as of 2026-08-06. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-03.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.